|
|
|
|
Headache relief was maintained 8,12,and 24 hours postdose with no use of rescue medication or a second dose of study medication by significantly(p< 0.001)greater percentages of patients after treatment with naratriptan 2. 5mg or 1mg compared with naratriptan 0.25mg or placebo.Naratriptan was also more effective than placebo in reducing clinical disability and the incidences of nausea,photophobia,and phonophobia.The overall incidence of adverse events and the incidences of specific adverse events did not differ in the naratriptan groups compared with placebo.No clinically relevant changes in ECG,blood pressure,or laboratory findings were reported.These data demonstrate that naratriptan is effective and well tolerated for the acute treatment of migraine.The 2.5mg dose was associated with superior efficacy,whereas its adverse event profile was similar to that of placebo. |
|